Tyme flops on can­cer drug da­ta; Lil­ly IND fil­ing trig­gers $8M pay­ment to part­ner Zymeworks

→ Tyme Tech­nolo­gies on Fri­day tout­ed “sub­stan­tial­ly im­proved sur­vival ben­e­fit” from its ex­per­i­men­tal drug SM-88 in a sin­gle arm study in ad­vanced pan­cre­at­ic can­cer pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER